Current evidence does not support routine clinical use of GLP-1 medications specifically for alcohol cravings, and patients with alcohol use disorder should be referred to evidence-based treatments including behavioral interventions, mutual support groups, and FDA-approved pharmacotherapies such as naltrexone, acamprosate, and disulfiram
By enhancing insulin sensitivity, reducing appetite, and slowing down digestion, tirzepatide weight loss can be remarkably effective
To date, just 13 state Medicaid programs cover GLP-1s to treat obesity, while all states cover the drugs to treat diabetes
Supplied as lyophilized powder for reconstitution, this vial is intended for in-vitro research and qualified clinic protocols where lower-concentration delivery is preferred including dose-escalation studies, tolerability baselines, and pilot metabolic investigations
After first puncture, use the vial within 28 days
Our B12 shots for hangovers can be a game-changer, helping you regain energy and clarity quickly